{"id":15597,"date":"2022-09-19T00:00:00","date_gmt":"2022-09-19T00:00:00","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/annex-1-and-contamination-control-strategy\/"},"modified":"2023-07-27T11:46:33","modified_gmt":"2023-07-27T11:46:33","slug":"annex-1-and-contamination-control-strategy","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/","title":{"rendered":"Annex 1 and Contamination Control Strategy"},"content":{"rendered":"\n<p>In the current regulatory framework, manufacturers are required to develop a set of control strategies to confirm their process performance and product quality.&nbsp;<\/p>\n\n\n\n<p>In particular, the new EU GMP Annex 1 introduces a \u201cContamination Control Strategy\u201d (CCS) approach to comply with these requirements by preventing microorganisms, pyrogens and particulates contamination in sterile medicinal products. Piero Iamartino, pharmaceutical consultant and <a href=\"https:\/\/eipg.eu\/\" target=\"_blank\" rel=\"noreferrer noopener\">EIPG <\/a>Technical and Professional Development Vice President, joined Making Connect for an interview focused on Annex 1 and CCS. In this conversation, he also introduced the EIPG initiatives in support of its associates.<\/p>\n\n\n\n<figure class=\"wp-block-embed is-type-wp-embed is-provider-spreaker wp-block-embed-spreaker\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" title=\"PODCAST PIERO IAMARTINO - EIPG MAKING CONNECT - Pharma Podcast\" src=\"https:\/\/widget.spreaker.com\/player?episode_id=51281665&#038;theme=light&#038;playlist=false&#038;cover_image_url=https%3A%2F%2Fd3wo5wojvuv7l.cloudfront.net%2Fimages.spreaker.com%2Foriginal%2F99a21e8531e51f4132227e41f8d01c45.jpg#?secret=1LqSMTtKE4\" data-secret=\"1LqSMTtKE4\" width=\"696\" height=\"1000\" frameborder=\"0\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Piero Iamartino, pharmaceutical consultant and EIPG Technical and Professional Development Vice President, joined Making Connect for an interview focused on Annex 1 and CCS<\/p>\n","protected":false},"author":6,"featured_media":15878,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[687],"tags":[688,689,690,614,691],"class_list":{"0":"post-15597","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eipg-news","8":"tag-annex1","9":"tag-ccs","10":"tag-contamination-control-strategy","11":"tag-eipg","12":"tag-piero-iamartino"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annex 1 and Contamination Control Strategy - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annex 1 and Contamination Control Strategy - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-19T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-27T11:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2352\" \/>\n\t<meta property=\"og:image:height\" content=\"1568\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redazione\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redazione\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\"},\"author\":{\"name\":\"Redazione\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60\"},\"headline\":\"Annex 1 and Contamination Control Strategy\",\"datePublished\":\"2022-09-19T00:00:00+00:00\",\"dateModified\":\"2023-07-27T11:46:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\"},\"wordCount\":102,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg\",\"keywords\":[\"annex1\",\"ccs\",\"Contamination Control Strategy\",\"EIPG\",\"Piero Iamartino\"],\"articleSection\":[\"EIPG NEWS\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\",\"name\":\"Annex 1 and Contamination Control Strategy - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg\",\"datePublished\":\"2022-09-19T00:00:00+00:00\",\"dateModified\":\"2023-07-27T11:46:33+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60\"},\"description\":\"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg\",\"width\":2352,\"height\":1568,\"caption\":\"Piero Iamartino\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annex 1 and Contamination Control Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60\",\"name\":\"Redazione\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g\",\"caption\":\"Redazione\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/maura-bernini\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annex 1 and Contamination Control Strategy - MakingPharmaIndustry","description":"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Annex 1 and Contamination Control Strategy - MakingPharmaIndustry","og_description":"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control","og_url":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2022-09-19T00:00:00+00:00","article_modified_time":"2023-07-27T11:46:33+00:00","og_image":[{"width":2352,"height":1568,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg","type":"image\/jpeg"}],"author":"Redazione","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Redazione","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/"},"author":{"name":"Redazione","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60"},"headline":"Annex 1 and Contamination Control Strategy","datePublished":"2022-09-19T00:00:00+00:00","dateModified":"2023-07-27T11:46:33+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/"},"wordCount":102,"commentCount":0,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg","keywords":["annex1","ccs","Contamination Control Strategy","EIPG","Piero Iamartino"],"articleSection":["EIPG NEWS"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/","url":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/","name":"Annex 1 and Contamination Control Strategy - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg","datePublished":"2022-09-19T00:00:00+00:00","dateModified":"2023-07-27T11:46:33+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60"},"description":"Piero Iamartino joined Making Connect for an interview focused on Annex 1 and Contamination Strategy Control","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2023\/07\/IAMARTINO.jpg","width":2352,"height":1568,"caption":"Piero Iamartino"},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/eipg-news\/annex-1-and-contamination-control-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Annex 1 and Contamination Control Strategy"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/12ccc8a46d01cd2d240a5b064438fb60","name":"Redazione","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/385a31cd755c5e17c9892452fa035dad200ba77019438da992e6cfeb2d35483e?s=96&d=mm&r=g","caption":"Redazione"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/maura-bernini\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=15597"}],"version-history":[{"count":1,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15597\/revisions"}],"predecessor-version":[{"id":15877,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/15597\/revisions\/15877"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/15878"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=15597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=15597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=15597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}